B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer

Annals of the New York Academy of Sciences

Volumn 1183, Issue , 2010, Pages 38-57

  Dilillo, David J ^a   Matsushita, Takashi ^a   Tedder, Thomas F ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Autoimmunity; B cells; CD5; Inflammation; Lymphoma; Regulatory cells

Indexed keywords

INTERLEUKIN 10;

ALLERGIC ENCEPHALOMYELITIS; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CELL MATURATION; CONTACT ALLERGY; ENTERITIS; IMMUNE RESPONSE; INFLAMMATORY DISEASE; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE FUNCTION; NONHUMAN; PHENOTYPE; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; TH1 CELL; TUMOR IMMUNITY;

MUS;

EID: 75749087574     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.05137.x     Document Type: Review

References (91)

1. LeBien, T.W. & T.F. Tedder. 2008. B-lymphocytes: How they develop and function. Blood 112: 1570-1579.
2. DiLillo, D.J. et al. 2008. Maintenance of long-lived plasma cells and serologicalmemory despite mature and memory B cell depletion during CD20 immunotherapy in mice. J. Immunol. 180: 361-371.
3. Liu, Y. et al. 1995. Gene-targeted B-deficient mice reveal a critical role for B cells in the CD4 T cell response. Int. Immunol. 7: 1353-1362.
4. Linton,P.J., J.Harbertson&L.M.Bradley. 2000.Acritical role for B cells in the development of memory CD4 cells. J. Immunol. 165: 5558-5565.
5. Crawford, A. et al. 2006. Primary T cell expansion and differentiation in vivo requires antigen presentation by B cells. J. Immunol. 176: 3498-3506.
6. + T cell activation in mice. Proc. Natl. Acad. Sci. USA 104: 20882-20887.
7. Homann,D. et al. 1998. Evidence for an underlying CD4 helper and CD8 T-cell defect in B-cell-deficient mice: failure to clear persistent virus infection after adoptive immunotherapy with virus-specific memory cells from μMT/μMT mice. J. Virol. 72: 9208-9216.
8. Bergmann, C.C. et al. 2001. Impaired T cell immunity in B cell-deficient mice following viral central nervous system infection. J. Immunol. 167: 1575-1583.
9. O'Neill, S.K. et al. 2007. Expression of CD80/86 on B cells is essential for autoreactive T cell activation and the development of arthritis. J. Immunol. 179: 5109-5116.
10. Linton, P.J. et al. 2003. Costimulation via OX40L expressed by B cells is sufficient to determine the extent of primary CD4 cell expansion and Th2 cytokine secretion in vivo. J. Exp. Med. 197: 875-883.
11. Katz, S.I., D. Parker & J.L. Turk. 1974. B-cell suppression of delayed hypersensitivity reactions. Nature 251: 550-551.
12. Neta, R. & S.B. Salvin. 1974. Specific suppression of delayed hypersensitivity: the possible presence of a suppressor B cell in the regulation of delayed hypersensitivity. J. Immunol. 113: 1716-1725.
13. Mizoguchi, A. & A.K. Bhan. 2006. A case for regulatory B cells. J. Immunol. 176: 705-710.
14. Serra, P.&P. Santamaria. 2006. To 'B' regulated: B cells as members of the regulatory workforce. Trends Immunol. 27: 7-10.
15. Mauri, C. & M.R. Ehrenstein. 2008. The 'short' history of regulatory B cells. Trends Immunol. 29: 34-40.
16. Lund, F.E. 2008.Cytokine-producingBlymphocytes-key regulators of immunity. Curr. Opin. Immunol. 20: 1-7.
17. Bouaziz, J.-D., K. Yanaba & T.F. Tedder. 2008. Regulatory B cells as inhibitors of immune responses and inflammation. Immunol. Rev. 224: 201-214.
18. Harris, D.P. et al. 2000. Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat. Immunol. 475-482.
19. + phenotype controls T celldependent inflammatory responses. Immunity 28: 639-650.
20. Matsushita, T. et al. 2008. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J. Clin. Invest. 118: 3420-3430.
21. Yanaba, K. et al. 2009. The development and function of regulatory B cells expressing IL-10 (B10 cells) requires antigen receptor diversity and TLR signals. J. Immunol. 182: 7459-7472.
22. Kuhn, R. et al. 1993. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75: 263-274.
23. Tedder, T.F., K.M. Haas & J.C. Poe. 2002. CD19-CD21 complex regulates an intrinsic Src family kinase amplification loop that links innate immunity with Blymphocyte intracellular calcium responses. Biochem. Soc. Trans. 30: 807-811.
24. Tedder, T.F., J.C. Poe & K.M. Haas. 2005. CD22: amultifunctional receptor that regulates B lymphocyte survival and signal transduction. Adv. Immunol. 88: 1-50.
25. Higuchi, T. et al. 2002. Cutting Edge: Ectopic expression of CD40 ligand on B cells induces lupus-like autoimmune disease. J. Immunol. 168: 9-12.
26. Fillatreau, S., D. Gray & S.M. Anderton. 2008. Not always the bad guys: B cells as regulators of autoimmune pathology. Nat. Rev. Immunol. 8: 391-397.
27. Fillatreau, S. et al. 2002. B cells regulate autoimmunity by provision of IL-10. Nat. Immunol. 3: 944-950.
28. Mauri, C. et al. 2003. Prevention of arthritis by interleukin 10-producing B cells. J. Exp. Med. 197: 489-501.
29. Brummel, R. & P. Lenert. 2005. Activation of marginal zone B cells from lupus mice with type A(D) CpGoligodeoxynucleotides. J. Immunol. 174: 2429-2434. (Pubitemid 40223993)
30. Evans, J.G. et al. 2007. Novel suppressive function of transitional 2 B cells in experimental arthritis. J. Immunol. 178: 7868-7878.
31. Gray, M. et al. 2007. Apoptotic cells protect mice from autoimmune inflammation by the induction of regulatory B cells. Proc.Natl. Acad. Sci.USA 104: 14080-14085.
32. Burke, F. et al. 2004. IL-10-producing B220+CD11c- APC in mouse spleen. J. Immunol. 173: 2362-2372.
33. - B cells: possible involvement in age-associated cytokine dysregulation. Int. Immunol. 9: 745-754.
34. Mizoguchi, A. et al. 2002. Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity 16: 219-230.
35. O'Garra, A. et al. 1990.Production of cytokines bymouse B cells: B lymphomas and normal B cells produce interleukin 10. Int. Immunol. 2: 821-832.
36. Brossay, L. et al. 1997.MouseCD1is mainly expressed on hemopoietic-derived cells. J. Immunol. 159: 1216-1224.
37. Amano, M. et al. 1998. CD1 expression defines subsets of follicular and marginal zone B cells in the spleen: β2-microglobulin-dependent and independent forms. J. Immunol. 161: 1710-1717.
38. Makowska, A. et al. 1999. CD1high B cells: a population of mixed origin. Eur. J. Immunol. 29: 3285-3294.
39. O'Garra, A. et al. 1992. Ly-1 B (B-1) cells are the main source of B cell-derived interleukin 10. Eur. J. Immunol. 22: 711-717.
40. Watanabe, R. et al. 2007. CD19 expression in B cells is important for suppression of contact hypersensitivity. Am. J. Pathol. 171: 560-570.
41. Zhang, X. et al. 2007. Type I interferons protect neonates from acute inflammation through interleukin 10-producing B cells. J. Exp. Med. 204: 1107-1118.
42. Asseman, C. et al. 1999. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J. Exp. Med. 190: 995-1004.
43. Cottrez, F. et al. 2000. T regulatory cells 1 inhibit a Th2- specific response in vivo. J. Immunol. 165: 4848-4853.
44. Fiorentino, D.F. et al. 1991. IL-10 inhibits cytokine production by activated macrophages. J. Immunol. 147: 3815-3822.
45. Asadullah, K.,W. Sterry & H.D. Volk. 2003. Interleukin- 10 therapy-review of a new approach. Pharmacol. Rev. 55: 241-269.
46. + TH1-like responses. J. Clin. Invest. 98: 1010-1020.
47. Bettelli, E. et al. 1998. IL-10 is critical in the regulation of autoimmune encephalomyelitis as demonstrated by studies of IL-10- and IL-4-deficient and transgenic mice. J. Immunol. 161: 3299-3306.
48. Johansson, A.C. et al. 2001. IL-10-deficient B10.Q mice develop more severe collagen-induced arthritis, but are protected from arthritis induced with anti-type II collagen antibodies. J. Immunol. 167: 3505-3512.
49. Berg, D.J. et al. 1995. Interleukin 10 but not interleukin 4 is a natural suppressant of cutaneous inflammatory responses. J. Exp. Med. 182: 99-108.
50. Tanaka,Y. et al. 1996. Effect of IL-10 on collagen-induced arthritis in mice. Inflamm. Res. 45: 283-288.
51. Pennline, K.J., E. Roque-Gaffney & M. Monahan. 1994. Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse. Clin. Immunol. Immunopathol. 71: 169-175.
52. Schwarz, A. et al. 1994. In vivo effects of interleukin- 10 on contact hypersensitivity and delayed-type hypersensitivity reactions. J. Invest. Dermatol. 103: 211-216.
53. Puliti, M. et al. 2002. Regulatory role of interleukin-10 in experimental group B streptococcal arthritis. Infect. Immun. 70: 2862-2868. (Pubitemid 34564142)
54. Mizoguchi, A. et al. 1997. Suppressive role of B cells in chronic colitis of T cell receptor α mutant mice. J. Exp. Med. 186: 1749-1756. (Pubitemid 27506287)
55. + dendritic cells. J. Exp. Med. 204: 3147-3156.
56. Uchida, J. et al. 2004. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptordependentmechanisms during anti-CD20 antibody immunotherapy. J. Exp. Med. 199: 1659-1669.
57. Hamaguchi, Y. et al. 2006. Antibody isotype-specific engagement of Fcγ receptors regulates B lymphocyte depletion during CD20 immunotherapy. J. Exp. Med. 203: 743-753.
58. Haas,K.M. et al. 2005. B-1a andB-1b cells exhibitdistinct developmental requirements and have unique functional roles in innate and adaptive immunity to S. pneumoniae. Immunity 23: 7-18.
59. - T lymphocytes. J. Immunol. 127: 1420-1423.
60. Williams, K.C., E. Ulvestad & W.F. Hickey. 1994. Immunology of multiple sclerosis. Clin. Neurosci. 2: 229-245.
61. Martin, F. & J.F. Kearney. 2002. Marginal-zone B cells. Nat. Rev. Immunol. 2: 323-335.
62. Martin, F. & J.F. Kearney. 2000. B-cell subsets and the mature preimmune repertoire. Marginal zone and B1 B cells as part of a "natural immune memory". Immunol. Rev. 175: 70-79.
63. Anderson,M.S.&J.A.Bluestone. 2005. TheNODmouse: a model of immune dysregulation. Annu. Rev. Immunol. 23: 447-485.
64. Courtenay, J.S. et al. 1980. Immunisation against heterologous type II collagen induces arthritis in mice. Nature 283: 666-668.
65. Dal Canto, M.C. et al. 1995. Two models of multiple sclerosis: experimental allergic encephalomyelitis (EAE) and Theiler's murine encephalomyelitis virus (TMEV) infection. A pathological and immunological comparison. Microsc. Res. Tech. 32: 215-229.
66. Wolf, S.D. et al. 1996. Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice. J. Exp. Med. 184: 2271-2278.
67. Lampropoulou, V. et al. 2008. TLR-activated B cells suppress T cell-mediated autoimmunity. J. Immunol. 180: 4763-4773.
68. + T cell colitis through interaction with regulatory T cell subsets. Proc.Natl. Acad. Sci.USA 102: 2010-2015.
69. Hussain, S. & T.L. Delovitch. 2007. Intravenous transfusion of BCR-activated B cells protects NOD mice from type 1 diabetes in an IL-10-dependent manner. J. Immunol. 179: 7225-7232.
70. Tian, J. et al. 2001. Lipopolysaccharide-activated B cells down-regulate Th1 immunity and prevent autoimmune diabetes in nonobese diabetic mice. J. Immunol. 167: 1081-1089.
71. Xiu, Y. et al. 2008. B lymphocytes depletion by CD20 monoclonal antibody prevents diabetes inNODmice despite isotype-specific differences in FcγR effector functions. J. Immunol. 180: 2863-2875.
72. Trentham, D.E., A.S. Townes & A.H. Kang. 1977. Autoimmunity to type II collagen an experimental model of arthritis. J. Exp. Med. 146: 857-868.
73. Yanaba, K. et al. 2007. B cell depletion delays collageninduced arthritis in mice: arthritis induction requires synergy between humoral and cell-mediated immunity. J. Immunol. 179: 1369-1380.
74. Inoue, S. et al. 2006. Inhibitory effects of B cells on antitumor immunity. Cancer Res. 66: 7741-7747.
75. Shah, S. et al. 2005. Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL and TH1 cytokine responses by B cells. Int. J. Cancer 117: 574-586.
76. Qin, Z. et al. 1998. B cells inhibit induction of T celldependent tumor immunity. Nat. Med. 4: 627-630.
77. DiLillo, D.J. & T.F. Tedder. 2009. B cells are required for T cell activation during tumor immunity. J. Immunol. 182: Abstract 88.27.
78. Minard-Colin, V. et al. 2008. Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcγRI, FcγRIII, and FcγRIV. Blood 112: 1205-1213.
79. Gillan,V., R.A. Lawrence&E.Devaney. 2005. B cells play a regulatory role in mice infected with the L3 of Brugia pahangi. Int. Immunol. 17: 373-382. (Pubitemid 40568112)
80. Mangan, N.E. et al. 2004. Helminth infection protects mice from anaphylaxis via IL-10-producing B cells. J. Immunol. 173: 6346-6356.
81. Hoerauf, A., M. Rollinghoff & W. Solbach. 1996. Cotransfer of B cells converts resistance into susceptibility in T cell-reconstituted, Leishmania major-resistant C.B- 17 scid mice by a non-cognatemechanism. Int. Immunol. 8: 1569-1575.
82. Burdin, N., F. Rousset & J. Banchereau. 1997. B-cellderived IL-10: production and function. Methods 11: 98-111.
83. + B cells. Lupus 12: 356-363.
84. Llorente, L. et al. 1994. In vivo production of interleukin- 10 by non-T cells in rheumatoid arthritis, Sjogren's syndrome, and systemic lupus erythematosus. A potential mechanism of B lymphocyte hyperactivity and autoimmunity. Arthritis Rheum. 37: 1647-1655.
85. + cells in patients with systemic lupus erythematosus. J. Autoimmun. 23: 379-383.
86. Gantner, F. et al. 2003. CD40-dependent and - independent activation of human tonsil B cells by CpG oligodeoxynucleotides. Eur. J. Immunol. 33: 1576-1585.
87. +) B cells. A major lymphoid subpopulation in human fetal spleen: phenotypic and functional studies. J. Immunol. 136: 505-510.
88. + B lymphocytes. Scand. J. Immunol. 49: 629-632.
89. Duddy, M.E., A. Alter & A. Bar-Or. 2004. Distinct profiles of human B cell effector cytokines: a role in immune regulation. J. Immunol. 172: 3422-3427.
90. Rieger, A. & A. Bar-Or. 2008. B-cell-derived interleukin- 10 in autoimmune disease: regulating the regulators.Nat. Rev. Immunol. 8: 486-487.
91. Matsushita, T. et al. 2006. Inhibitory role of CD19 in the progression of experimental autoimmune encephalomyelitis by regulating cytokine response. Am. J. Pathol. 168: 812-821.